Evaluating a new injectable contraceptive for women
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - UTAH
This study is testing a new long-lasting birth control shot called levonorgestrel butanoate, especially for women who are overweight and at risk for blood clots, to see if it works well and is safe without the added hormones found in other methods.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11337219 on NIH RePORTER |
What this research studies
This research investigates a new long-acting injectable contraceptive called levonorgestrel butanoate, designed specifically for women, particularly those who are obese and at risk for venous thromboembolism (VTE). The study aims to provide an estrogen-free alternative to traditional contraceptive methods, which often require strict adherence and may pose additional health risks. By focusing on a population that has limited options, the research seeks to assess the efficacy and safety of this new formulation in a clinical trial setting. Participants will be monitored for adherence and contraceptive effectiveness over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of childbearing age who are obese and seeking effective contraception without the risks associated with estrogen.
Not a fit: Patients who are not obese or those who do not require contraception may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more convenient contraceptive option for women, especially those who are obese.
How similar studies have performed: Previous research has shown success with other long-acting contraceptive methods, but this specific formulation is novel and aims to address a unique patient population.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Turok, David — University of Utah
- Study coordinator: Turok, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.